OUR DRUG PIPELINE
Promising disease product candidates for difficult to treat diseases
ANV221 - Targeting the Cancer Glycobiome
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)
*Oncotarget. 2016; 7:35478-35489. https://doi.org/10.18632/oncotarget.8155
Several solid tumor cancers have been found to upregulate N-glycosylation to fuel one or more of their hallmark behaviors. ANV221 is a novel drug candidate that interrupts this cycle in vivo models leading to:
-
Disruption of chronic proliferation signaling
-
Activation of evolutionary conserved apoptosis (cell suicide) pathways
-
Suppressing cell invasiveness, migration and metastasis
-
Reversing stem like transformations, thus enhancing tumor vulnerability to other cytotoxic therapies
-
Low observed toxicity
ANV221 was awarded Orphan Drug Designation for the treatment of Pancreatic Cancer by the FDA.
"PDAC xenograft tumors were disappeared in two weeks."
- Michio Kurosu, PhD University of Tennessee Health Science Center
Viruses and DPAGT1
Two virus families, coronavirus and flavivirus are known to upregulate N-glycosylation. Read our white paper to learn how these viruses may respond to DPAGT1 inhibitors.